Status:

COMPLETED

Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy

Lead Sponsor:

Robert Pendleton

Collaborating Sponsors:

University of Louisville

Conditions:

Blood Clotting

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Warfarin is the most commonly used oral anticoagulant medicine (blood thinner). Although this medicine works well, it is difficult to know how much medicine a patient needs. Many things affect how muc...

Detailed Description

Warfarin is the most commonly used oral anticoagulant medication. Due to the difficulty in determining an individual's proper warfarin dose, therapy is typically initiated with a standard dose followe...

Eligibility Criteria

Inclusion

  • Prescribed warfarin for any indication, so long as they are naïve to the drug at enrollment and are expected to receive therapy for at least 12 weeks

Exclusion

  • Recent cardiothoracic surgery as indication for warfarin.

Key Trial Info

Start Date :

August 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2010

Estimated Enrollment :

26 Patients enrolled

Trial Details

Trial ID

NCT00993200

Start Date

August 1 2009

End Date

December 1 2010

Last Update

June 24 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Utah

Salt Lake City, Utah, United States, 84132